Driehaus Capital Management’s NovoCure NVCR Stock Holding History

Driehaus Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,840	Closed	-$586K	–	552
2019 Q3	$586K	Sell	7,840 -5,760	-42%	-$461K	0.02%	397
2019 Q2	$860K	Buy	+13,600	New	+$689K	0.03%	287
2018 Q4	–	Sell	-155,817	Closed	-$8.16M	–	483
2018 Q3	$8.16M	Buy	155,817 +112,545	+260%	+$4.48M	0.25%	129
2018 Q2	$1.35M	Buy	+43,272	New	+$1.2M	0.05%	311
2017 Q3	–	Sell	-43,211	Closed	-$748K	–	560
2017 Q2	$748K	Buy	+43,211	New	+$558K	0.03%	374

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Driehaus Capital Management's NVCR Position: Q4 2019 in Review

Driehaus Capital Management sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 7,840 shares — an estimated $586K sold.

Driehaus Capital Management first reported a position in NVCR in Q2 2017 and held it in 5 quarters. The position peaked at $8.16M in Q3 2018. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

Driehaus Capital Management reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
Driehaus Capital Management sold 7,840 NovoCure shares in Q4 2019, an estimated $586K.
Driehaus Capital Management first reported a position in NovoCure in Q2 2017 and held it in 5 quarters.
Driehaus Capital Management's NovoCure position peaked at $8.16M in Q3 2018.
262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Driehaus Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.